← Back to Search

Lung Protective Ventilation for Traumatic Brain Injury (NEUROVENT Trial)

N/A
Waitlist Available
Led By Colin K Grissom, MD
Research Sponsored by Colin Grissom
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up hospital admission through 90 days
Awards & highlights

NEUROVENT Trial Summary

This trial is testing a computerized ventilator protocol in iCentra that is designed to improve outcomes for patients with acute brain injury by targeting a normal partial pressure of carbon dioxide while using the lowest ventilator volume required.

Who is the study for?
This trial is for adults (18+) with acute brain injury, either from non-traumatic causes like stroke or anoxic brain injury, or from traumatic events. They must be starting mechanical ventilation in the emergency department or ICU at an Intermountain Healthcare hospital.Check my eligibility
What is being tested?
The study tests a computerized ventilator protocol aiming to maintain normal carbon dioxide levels in blood while using the lowest necessary ventilator volume. It's designed to prevent further lung damage and improve outcomes for patients with acute brain injuries.See study design
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort due to lower ventilator volumes and possible complications if optimal carbon dioxide levels are not maintained.

NEUROVENT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~hospital admission through 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and hospital admission through 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tidal Volume
Secondary outcome measures
Average number of protocol deviations for all subjects (protocol compliance)
Costs of Care
Health Care Utilization
+7 more

NEUROVENT Trial Design

1Treatment groups
Experimental Treatment
Group I: Lung Protective VentilationExperimental Treatment1 Intervention
Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lung Protective Ventilation
2018
N/A
~20

Find a Location

Who is running the clinical trial?

Colin GrissomLead Sponsor
Colin K Grissom, MDPrincipal InvestigatorIntermountain Health Care, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment phase for this study still ongoing?

"The clinical trial is presently not open for enrollment, as detailed on clinicaltrials.gov. Initial registration occurred on 31st August 2017 with the latest update recorded on 23rd February 2021. While this specific trial is no longer active in recruitment, there exist a substantial number of 2390 ongoing studies seeking participants at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Implementation of Neuro Lung Protective Ventilation
Colin Grissom 2017. "Implementation of Neuro Lung Protective Ventilation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03243539.
All > Stroke
~96 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top